Nine-Year Outcomes with Nivolumab in Melanoma

Long-term results from the phase III CheckMate 238 study provide more than nine years of follow-up in patients with resected stage III or IV melanoma. In this MEDtalk, Paolo Ascierto, MD, Professor of Oncology, University Federico II of Naples, Italy, presents results showing that adjuvant nivolumab continued to demonstrate a significant improvement in relapse-free survival compared with ipilimumab.